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STRUCTURED ABSTRACT
Objectives—We evaluated whether carotid intima-media thickness (C-IMT) and the presence or
absence of plaque improved coronary heart disease (CHD) risk prediction when added to
traditional risk factors (TRF).
Background—Traditional CHD risk prediction schemes need further improvement as the
majority of the CHD events occur in the “low” and “intermediate” risk groups. C-IMT and
presence of plaque on an ultrasound are associated with CHD and therefore could potentially help
improve CHD risk prediction.
Methods—Risk prediction models (overall, in men and women) considered included TRF-only,
TRF+C-IMT, TRF+plaque, and TRF+C-IMT+ plaque. Model predictivity was determined by
calculating the area under the receiver operating characteristic curve (AUC) adjusted for
optimism. Cox-proportional hazards models were used to estimate 10-year CHD risk for each
model, and the number of individuals reclassified determined. Observed events were compared
with expected events; and, the net reclassification index (NRI) was calculated.
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Results—Of 13,145 eligible individuals (5,682 men; 7,463 women), ~23% were reclassified by
adding C-IMT+plaque information. Overall, the addition of C-IMT and plaque separately or
together to the TRF model improved the AUC which increased from 0.742 to 0.750, 0.751 and
0.755 for the TRF-only, TRF+C-IMT, TRF+plaque and TRF+C-IMT+plaque model respectively.
The C-IMT+TRF+plaque model had a NRI of 9.9% when compared to TRF-only in the overall
population. However, comparison of TRF+C-IMT+plaque with TRF+C-IMT or TRF+plaque only
resulted in non-significant or modestly significant changes of the various statistical tests. Sex-
specific analyses are presented in the manuscript.
Conclusion—Adding plaque and C-IMT to TRF improves CHD risk prediction in the ARIC
study.
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C-IMT; plaque; risk prediction
INTRODUCTION
Traditional risk prediction scores such as the Framingham risk score have proven very
useful in identifying individuals at risk for coronary heart disease (CHD), but such risk
scores have limitations. Biomarkers, imaging and genotypes are being examined to try to
improve CHD risk prediction (1–6).
Carotid intima-media thickness (C-IMT) is a well-described surrogate marker for
cardiovascular disease, and increased C-IMT has been associated with prevalent and
incident CHD and stroke (7,8). Further, statins, which reduce major adverse cardiovascular
events (9) have been shown to stabilize and regress C-IMT. Although reports (3,4) have
suggested that adding C-IMT, by improving the area under the receiver operating
characteristics curve, can improve risk prediction from a clinical decision-making
standpoint, the ability of a marker to reclassify an individual’s risk group is critical (10).
Furthermore, plaque presence, which has been shown to be associated with CHD
independent of C-IMT measurements in several studies, (11) has not been adequately
evaluated in risk classification especially using contemporary criteria for evaluating novel
cardiovascular risk markers (12). We investigated whether C-IMT and information about the
presence or absence of plaque improves CHD risk prediction in the ARIC study.
METHODS
Subjects
The ARIC study is an epidemiologic study of cardiovascular disease incidence which
recruited a population-based cohort of 15,792 individuals aged between 45–64 years from 4
U.S. communities between 1987 and 1989. A complete description of the study design,
objectives and sampling strategy have been previously described (13). For this analysis, we
excluded individuals with prevalent CHD or prevalent stroke (n= 763), missing prevalent
CHD data (n= 339), missing C-IMT or plaque data (n= 909), missing information on
traditional CHD risk factors (TRF) (n = 533), races other than “black” or “white” (n=48) and
black participants from the Minnesota or Washington field center (n=55) which provided us
with a sample of 13,145 individuals for the analysis.
Ultrasound measurement
The ultrasound procedure in the ARIC study has been previously described (14–17). Briefly,
a Biosound 2000IISA system was used and images recorded on a VHS tape. C-IMT was
Nambi et al. Page 2













measured centrally by trained readers at the ARIC Ultrasound Reading Center. The C-IMT
was assessed in 3 segments: the distal common carotid (1 cm proximal to dilation of the
carotid bulb), the carotid artery bifurcation (1 cm proximal to the flow divider) and the
proximal internal carotid arteries (1 cm section of the internal carotid artery immediately
distal to the flow divider). At each of these segments, 11 measurements of the far wall (in 1
mm increments) were attempted. The mean of the mean measurements across these
segments of both right and the left sides were estimated. Trained readers adjudicated plaque
presence or absence if 2 of the following 3 criteria were met: abnormal wall thickness
(defined as C-IMT >1.5mm), abnormal shape (protrusion into the lumen, loss of alignment
with adjacent arterial wall boundary), and abnormal wall texture (brighter echoes than
adjacent boundaries) (11,15). The reproducibility and variation of C-IMT and plaque
measurements in the ARIC study have been previously published (15,18). The site-specific
reliability coefficients was estimated as 0.77, 0.73 and 0.70 for the mean carotid far wall
IMT at the carotid bifurcation, internal carotid arteries, and common carotid arteries,
respectively. For the presence or absence of plaque, the intra-reader agreement was
associated with a κ statistic of 0.76, while the inter-reader agreement was 0.56, which
suggests good agreement beyond chance.
Ascertainment of incident CHD events
Incident CHD events included definite or probable myocardial infarction (MI), silent MI
between examinations indicated by electrocardiograms, definite CHD death, or coronary
revascularization. The methods by which the incident CHD events were ascertained and
classified and the details of quality assurance have been previously published (19). Briefly,
participants were contacted annually, and discharge lists from local hospitals and death
certificates were surveyed to look for incident CHD events. Follow-up for this analysis was
until December 31st 2005.
Statistical analysis
The analyses were performed in the entire study sample and then by gender. The ARIC
coronary risk score (ACRS) developed by Chambless et al (4) in the ARIC cohort, is similar
to the Framingham risk score and includes age, age2, sex, systolic blood pressure,
antihypertensive medication use, total cholesterol, high-density lipoprotein cholesterol
(HDL-C), gender, diabetes, and smoking status. The ACRS variables were used in the
“TRF-only” risk prediction model in our analysis as it would represent the best TRF-based
model in the ARIC study for CHD prediction. However, we also evaluated adding C-IMT
and plaque to a Framingham risk score (FRS)-based TRF model since the FRS is
traditionally used by most clinicians.
Several models were considered: 1) TRF+(sex-specific) C-IMT, categorized as <25th
percentile, 25–75th percentile, >75th percentile; 2) TRF+plaque; and, 3) TRF+C-IMT (sex-
specific and categorized as previously stated)+plaque. We described the area under the
receiver operator characteristic curve (AUC) for 10-year risk using methods which
accounted for censoring (20) for each of the models to describe the model predictivity.
Bootstrapping was performed to obtain confidence intervals for the differences in adjusted
AUC between the models and to adjust for the over-optimism that can occur when the fit of
the model is tested using the same data in which it was described (21–23).
Using Cox-proportional hazards, the 10-year CHD risk for each of the models was
calculated, and individuals classified into 0–5% (“low” risk), 5–10% (“low-intermediate”
risk), 10–20% (“intermediate-high” risk) and >20% (“high”) risk. The number of individuals
who changed risk groups (i.e., reclassified after adding C-IMT and plaque data) was then
described. To test the model calibration, we compared the “goodness-of-fit” of the observed
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and expected number of events within estimated risk decile groups using the Grønnesby-
Borgan statistic (24). Large values of the test statistic (i.e., significant ‘p’ values) suggest
poor model fit. We then calculated the net reclassification index (NRI) which examines the
net effect of adding a marker to the risk prediction scheme using a statistic described by
Pencina et al (25) except estimated by a method accounting for censoring (Personal
Communication). We also described the “clinical NRI” or the NRI in the groups defined as
intermediate (5–10% and 10–20% estimated CHD risk based on the model prior to
reclassification) in risk (i.e., the groups in which the addition of a marker may be of most
use). Finally, we also estimated the “integrated discrimination improvement” (IDI) (25)
(again accounting for censoring) which is the difference in an R2-like statistic between the
traditional and expanded models. AUC, NRI, and IDI were calculated for 10-year follow-up
and confidence intervals were furnished by bootstraping.
RESULTS
The study sample’s baseline characteristics are listed in Table 1. The 25th and 75th percentile
C-IMT of the 5,682 men and 7,463 women (13,145 total individuals) were 0.65 mm and
0.84 mm for men and 0.58 mm and 0.74 mm for women, respectively. Atherosclerotic
plaque presence increased from 13.6% in the overall population with a C-IMT<25th
percentile (17.4% in men, 10.7% in women), to 26.2% in those with a C-IMT between 25–
75th percentile (33.5% for men and 20.7% for women), and to 65.3% in those with a C-IMT
> 75th percentile (73.1% in men and 59.5% in women) respectively. When evaluated by risk
groups, plaque prevalence increased from 24% in the 0–5% risk group to 34.3% in the 5–
10%, 46.5% in the 10–20% and 54.6% in the >20%, 10-year CHD (high) risk groups,
respectively.
Over a mean follow-up period of 15.1 years (men=14.4 years, women=15.7 years), there
were 1,812 incident CHD events (867 definite or probable MI’s, 159 CHD deaths, 688
coronary revascularizations, and 98 silent [ECG-confirmed] MI’s).
When examining the AUC, adding C-IMT and/or plaque information (individually and
together) to TRF improved the AUC significantly (even after adjustment for optimism) in
both men and women, except that adding C-IMT alone in women was not significant (Table
2). Adding plaque to TRF had a more pronounced effect than adding C-IMT to TRF on the
AUC in women. In women, the AUC increased from 0.759 (TRF alone) to 0.762 (95%
confidence interval [CI] for the difference in adjusted AUC, −0.002, 0.006) when C-IMT
was added to TRF while the AUC increased to 0.770 (95% CI for the difference in adjusted
AUC, 0.005, 0.016) for plaque alone + TRF. The TRF + C-IMT + plaque model was
associated with a similar AUC of 0.770 (0.005, 0.017). On the other hand, adding C-IMT
had a more pronounced effect than adding plaque to TRF on the AUC in men. In men, the
AUC increased from 0.674 (TRF alone) to 0.690 (95% CI for the difference in adjusted
AUC 0.009, 0.022) when C-IMT was added to TRF while the AUC increased to 0.686 (95%
CI 0.005, 0.017) for plaque alone+TRF. The TRF+C-IMT+plaque model was associated
with the most increase in AUC which increased to 0.694 (95% C.I. 0.011, 0.027). When we
considered the addition of plaque to a model that included TRF+C-IMT, it significantly
improved the AUC in women by 0.009 (95% CI 0.003, 0.012), while in men, the increase in
AUC by 0.004 (95% CI −0.001, 0.006) was non-significant. On the other hand, when we
considered the addition of C-IMT to a model that included TRF+plaque, it improved the
AUC in men by 0.008 (95% CI 0.002, 0.011), while in women, the increase in AUC by
0.000 (95% CI −0.002, 0.002) was non-significant.
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The CHD incidence rate per 1,000 person years in the various C-IMT categories taking into
account the presence or absence of plaque is described in Figure 1. In all C-IMT categories,
the presence of plaque was associated with a higher incidence of CHD events.
Adding plaque information along with C-IMT to TRF resulted in the reclassification of
8.6%, 37.5%, 38.3% and 21.5% of the overall sample in the <5%, 5–10%, 10–20% and
>20% 10-year estimated risk groups, respectively (Table 3A), while adding plaque and C-
IMT reclassified 17.4%, 32.8%, 36.6% and 25.2% of the men (Table 3B) and 5.1%, 40.2%,
38.4% and 24.9% of the women (Table 3C) in the same risk groups. Overall, more
individuals were reclassified to a lower risk group (~12.4%) than to a higher risk group
(~10.8%), and nobody was reclassified from the low risk group (<5% estimated 10-year
CHD risk) to the high risk (>20%, 10-year estimated CHD risk) or vice versa.
We then examined the goodness-of-fit of the various models using the Grønnesby-Borgan
statistic. When the overall population was considered, although model fit improved with the
addition of C-IMT and/or plaque, none of the models had a good fit with the Chi-square
statistic (p-value) being 30.0 (p=0.0004), 23.7 (p=0.005) and 24.3 (p=0.004) for the TRF
only model, TRF + C-IMT model and TRF + C-IMT + plaque model, respectively. When
men and women were considered separately, the model fit improved. In men, the C-IMT +
TRF model was the best fit (Chi-square statistic=14.12, p=0.11), while the C-IMT+TRF
+plaque model and TRF-only model were not as good fits (Chi-square statistic [p-values] =
17.9 [p=0.04] and 18.7 [p=0.028], respectively). On the other hand, in women, the Chi-
square test statistic (p values) were 15.0 (p=0.09), 9.1 (p=0.43) and 8.7 (p=0.47) for the TRF
only, TRF + C-IMT and TRF + C-IMT + plaque models, respectively, which suggested that
the TRF+C-IMT+plaque model had the best model fit.
Finally, we examined the NRI and the clinical NRI (NRI in the intermediate groups). We
compared several models (Table 4) and found that the TRF+C-IMT+plaque model was
better than the TRF-only model in the overall sample, in men, and in women. However,
adding plaque data minimally affected the TRF+C-IMT model in men, while adding C-IMT
information minimally affected the TRF+plaque model in women. Overall, the TRF+C-IMT
+plaque model when compared to the TRF-only model was associated with significant
NRI’s of 9.9% (clinical NRI 21.7%) in the overall sample, 8.9% (clinical NRI 16.4%) in
men and 9.8% (clinical NRI 25.4%) in women. In the overall sample, adding C-IMT or
plaque individually to TRF was associated with a significant NRI of ~7.1–7.7% while
adding the second variable (i.e. plaque to a TRF+C-IMT model or C-IMT to a TRF+plaque
model) non-significantly increased the NRI by about 2–3%. The IDI showed that the model
predictivity was significantly improved by adding C-IMT and plaque to TRF: in the overall
population the IDI was 0.011, while in women, it was 0.009; and, in men, 0.013
(Supplemental Table).
When we added C-IMT and plaque information to a Framingham risk score (FRS)-based
TRF model, the results were similar. The adjusted AUC in men and women using the FRS
model alone were 0.661 and 0.741, respectively, and improved to 0.685 (95% confidence
interval [CI] for the difference in adjusted AUC, 0.014, 0.032) and 0.751 (95% confidence
interval [CI] for the difference in adjusted AUC, 0.003, 0.016) respectively by adding C-
IMT and plaque. In men, 11.5%, 34%, 37.9% and 32% of those in the <5%, 5–10%, 10–
20% and >20% FRS categories respectively were reclassified by adding C-IMT and plaque,
resulting in a NRI of 12.7% and a clinical NRI of 18.9%. However, in women, 6.6%, 41%,
39.8% and 36.3% of those in the <5%, 5–10%, 10–20% and >20% FRS categories
respectively were reclassified, resulting in a NRI of 7.7% and a clinical NRI of 21.2%.
Finally, when the goodness-of-fit was tested using the Grønnesby-Borgan test statistic, the
model with FRS+C-IMT+plaque was better than the FRS-only model in both men (Chi-
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square statistic for FRS only = 15.05, p=0.09, Chi-square statistic for FRS+C-IMT+plaque
=10.18, p=0.34) and women (Chi-square statistic for FRS only = 8.63, p=0.47, Chi-square
statistic for FRS+C-IMT+plaque =4.97, p=0.84).
DISCUSSION
Although CHD risk prediction models based on “traditional risk factors” have formed the
basis for the clinical practice of CHD prevention they are far from optimal (26). Several
efforts have looked at adding biomarkers to improve cardiovascular risk prediction (1,2),
and other recent efforts have examined the use of genetic markers as well (5). Of these, hs-
CRP has shown the most promise.
Imaging tests such as carotid artery ultrasound and coronary calcium score offer another
marker that could be used in improving CHD risk prediction by directly visualizing
atherosclerosis. Although several efforts have examined the use of these imaging modalities,
there is limited data using contemporary statistical methodology that have evaluated whether
the addition of imaging markers to risk models can improve risk prediction. Furthermore,
most of the studies examining C-IMT have had limited CHD events in follow up and did not
utilize information about plaque presence or absence.
We now show that, in the 13,145 ARIC participants followed for ~15 years, using C-IMT
and plaque information can improve CHD risk prediction. Adding C-IMT and plaque
information resulted in the reclassification of ~23% of the individuals with a net
reclassification improvement of ~9.9%. However, it must be noted that more individuals
were reclassified to a lower risk group than to a higher risk group. Almost 61.9% of those
reclassified from the intermediate risk group (5–20% estimated 10 year CHD risk) were
reclassified to lower risk. Furthermore, nobody from the low-risk group was reclassified to a
high-risk group, and nobody from the high-risk group was reclassified to the low-risk group.
Plaque presence seemed to have a more profound effect in improving risk prediction in
women than men and it is not completely clear why. There are likely several possible
explanations: One possible explanation is that perhaps, since middle-aged women have a
relatively low prevalence of atherosclerosis, plaque presence, which reflects a definite area
of atherosclerosis, was more powerful than using a sex-specific percentile “thickness” (C-
IMT). Similarly, given the overall lower prevalence of atherosclerosis in women, it is
possible that a C-IMT >75th percentile misclassifies individuals without atherosclerosis as
higher risk, and a specific C-IMT cutpoint may be better in women. However, it is clear that
when one considers the intermediate risk groups, the groups in which one would advocate
further risk stratification, adding plaque and C-IMT data best improved risk prediction in
men and women.
Overall, the NRI and clinical NRI (9.9% and 21.7% respectively, in the overall sample
population when the TRF+C-IMT+plaque model was compared to the TRF-only model)
was similar to other recent strategies that have been used in improving risk prediction (2,25).
Coronary calcium score is another imaging test used in clinical practice to identify higher
risk individuals. A recent study reported that coronary calcium score was a better predictor
of incident cardiovascular events, especially CHD events, when compared to C-IMT (6).
However, this study did not consider plaque presence or absence. Furthermore, the overall
number of incident cardiovascular disease events was only 222, included angina, and the
follow-up was shorter. Other reports comparing the two modalities have yielded mixed
results (27,28). Hence, a more long term comparison of coronary calcium scores with C-
IMT+plaque in the prediction of cardiovascular risk will be instructive. In addition, several
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other factors including cost-effectiveness and safety and feasibility of testing will all need to
be considered in identifying the role these imaging tests may have in risk stratification.
Finally, although current guidelines (29) suggest that individuals with a 0–10% predicted
10-year risk should be considered “low” in risk, reports suggest that there is a spectrum of
risk in the 0–10% risk group, and therefore 5–20% 10-year estimated risk should be
considered the “intermediate” risk group (1,30,31). Therefore, we divided the 0–10% risk
group into 0–5% (low risk group) and 5–10% estimated (low-intermediate risk) risk groups.
Plaque prevalence was almost ~10% higher in the 5–10% risk group (34% prevalence) when
compared to the 0–5% predicted risk group (24% prevalence).
In summary, our data suggests that: 1. Adding C-IMT and/or plaque information
individually and together to TRF improves CHD risk prediction; 2. Adding both C-IMT and
plaque provides the most improvement but adding the second variable (i.e. C-IMT to a TRF
+plaque model or plaque to a TRF+C-IMT model) results in minimal/modest improvements
only; 3.As with other markers, the addition of C-IMT/plaque maybe most valuable in the
intermediate-risk groups. Overall the improvement in risk prediction may be equivalent to
other contemporary markers.
In the future, further improvement in our ability to stratify CHD risk may be possible
through reliable quantification of plaque volume since the mere presence of plaque without
any quantification helped improve overall CHD risk prediction in our analysis.
The strengths of our study include the use of contemporary statistical methodology (12), the
long follow up and the number of incident CHD events accrued over the time period.
Furthermore, we examined the ability of C-IMT and plaque to improve risk prediction when
added to both the ACRS- and FRS-based TRF models. Finally, diabetes is included in the
ACRS-based TRF model; although this is considered a CHD risk equivalent, we chose to
include diabetes in the model in order for us to evaluate whether adding C-IMT and plaque
can improve the best CHD prediction model in the ARIC study.
Limitations
We used data from the baseline ARIC visit for this analysis. We have not accounted for
changes in the risk factors over the time period of this analysis or changes in the medications
during this time period. However, this is similar to any risk prediction scheme that has been
described. Recent data (32) suggests that persons with an increased lifetime risk may have a
higher burden of sub-clinical atherosclerosis. We did not consider “lifetime risk,” but adding
C-IMT and plaque data helped to better identify those at short term risk and hence, may
have additional value over the estimation of lifetime risk. We did not account for the
potential difference between plaque presence in one artery alone versus multiple arteries. It
is possible that plaque presence in multiple carotid artery segments may be associated with a
higher risk. Several individuals (n=909) had missing C-IMT data, and we do not know how
their presence in the study would have impacted the results. Finally, at this time, there is no
clinical study evidence that shows whether treating individuals by this strategy based on the
identification of “higher” risk will prevent incident cardiovascular events; although, one
would expect this to be the case.
Conclusion
Carotid ultrasound based–C-IMT measurement and identification of plaque presence or
absence improves CHD risk prediction in the ARIC study and should be considered in the
intermediate risk (5–20% estimated 10-year CHD risk) group. Ultrasound-based risk
stratification strategies should be tested in clinical trials to evaluate whether improved
prevention of cardiovascular events is possible.
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Adjusted coronary heart disease incidence rate per 1,000 person year adjusted by C-IMT
categories (<25th percentile, 25–75th percentile and >75th percentile) with and without
plaque
- The figure shows that, at every C-IMT category (i.e., <25th percentile, 25–75th percentile
and >75th percentile), for the overall group, men or women, having carotid artery plaque is
associated with higher incidence of coronary heart disease.
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Table 1








Age (years) 54.42 (5.8) 53.75 (5.7) 54.0 (5.8)
Body mass index (kg/m2) 27.23 (4.0) 27.46 (5.8) 27.36 (5.1)
Systolic blood pressure
(mmHg)
122.1 (17.7) 119.7 (19.1) 120.72 (18.6)
Diastolic blood pressure
(mmHg)
75.5 (11.2) 71.9 (10.9) 73.46 (11.2)
Total cholesterol (mg/dl) 210.2 (39.4) 217.0 (42.1) 214.0 (41.1)
Triglycerides (mg/dl) 130.4 (67.0) 117.1 (60.5) 122.9 (63.7)
High density lipoprotein
cholesterol (mg/dl)
45.3 (13.9) 58.2 (17.2) 52.6 (17.1)
Low density lipoprotein
cholesterol (mg/dl)







Fasting Glucose (md/dl) 106.3 (28.0) 104.1 (32.6) 105.0 (30.7)
Whites (%) 77.7% 72.6% 74.8%
Diabetes (%) 10.3% 10.0% 10.1%
Current tobacco use (%) 27.6% 25.0% 26.1%
Former tobacco use (%) 43.2% 22.48% 31.5%
Cholesterol Lowering Medication Use (%) 2.3% 2.6% 2.4%
Aspirin Use (%) 41.1% 49.4% 45.8%
Statin Use (%) 0.3% 0.6% 0.5%
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Table 2
Adjusted area under the curve (AUC) for different models with confidence intervals for the difference in
adjusted AUC
Model Overall Men Women
AUC for the various models and 95% CI for difference in adjusted AUC comparing the
various models with TRF only model
TRF only 0.742 0.674 0.759
TRF+C-IMT 0.750 (0.005, 0.012) 0.690 (0.009, 0.022) 0.762 (−0.002, 0.006)
TRF+Plaque 0.751 (0.006, 0.013) 0.686 (0.005, 0.017) 0.770 (0.005, 0.016)
TRF+C-IMT+
Plaque 0.755 (0.008, 0.017) 0.694 (0.011, 0.027) 0.770 (0.005, 0.017)
TRF+IMT+Plaque vs. TRF+IMT
(0.001, 0.006) (−0.001, 0.006) (0.003, 0.012)
TRF+IMT+Plaque vs. TRF+Plaque
(0.001, 0.005) (0.002, 0.011) (−0.002, 0.002)
TRF= traditional risk factors
C-IMT= carotid intima media thickness
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